BCRX
Biocryst Pharmaceuticals margins
- Stocks
- Healthcare
- NASDAQ: BCRX
- Margins
Biocryst Pharmaceuticals reports a gross margin of 97.9%, an operating margin of -30.1%, an EBITDA margin of -28.7%, and a net margin of -37.4%, while its operating margin is negative at -30.1%, its EBITDA margin is negative at -28.7%, and its net margin is negative at -37.4%. Gross margin increased the most, by 0.5 percentage points, while operating margin fell the most, by 42.8 percentage points.
BCRX margin history
Over the last 3 years, Biocryst Pharmaceuticals's margins averaged 97.82% gross, -10.12% operating, -8.93% EBITDA, and -27.78% net. Currently, gross margin is above its three-year average, while operating, EBITDA, and net margins are below their three-year averages.
BCRX margin expansion
Biocryst Pharmaceuticals's gross margin expanded by 0.5 percentage points, but operating margin contracted by 42.8 percentage points, EBITDA margin by 42.7 percentage points, and net margin by 35.9 percentage points.
BCRX Gross margin
Over the last 3 years, the average gross margin for Biocryst Pharmaceuticals was 97.82%. The latest gross margin for Biocryst Pharmaceuticals is 97.9%, 0.1 percentage points above its three-year average. Biocryst Pharmaceuticals's gross margin ranged from a low of 96.9% in Mar 2025 to a high of 98.6% in Mar 2024.
BCRX Operating margin
Biocryst Pharmaceuticals recorded an average operating margin of -10.12% across the last 3 years. Biocryst Pharmaceuticals currently reports an operating margin of -30.1%, 20 percentage points below its three-year average. Over the last 3 years, Biocryst Pharmaceuticals's operating margin peaked at 39% in Dec 2025 and reached a low of -43.1% in Mar 2026.
BCRX EBITDA margin
Across the last 3 years, Biocryst Pharmaceuticals's EBITDA margin came to -8.93%. Biocryst Pharmaceuticals's current EBITDA margin is -28.7% and is 19.8 percentage points below its three-year average. EBITDA margin was highest at 39.7% in Dec 2025 and lowest at -42.6% in Mar 2026.
BCRX Net margin
Looking at the last 3 years, Biocryst Pharmaceuticals had an average net margin of -27.78%. Against its three-year average, Biocryst Pharmaceuticals's net margin is currently -37.4%, 9.6 percentage points below its three-year average. Looking back over the last 3 years, Biocryst Pharmaceuticals's net margin reached 30.2% at its highest point in Dec 2025 and -68.4% at its lowest in Dec 2023.
BCRX margin group comparison
Biocryst Pharmaceuticals's gross margin of 97.9% is higher than the Healthcare sector, the industry and its peers average. In comparison with the Healthcare sector average of 68.4%, Biocryst Pharmaceuticals's gross margin is 43% higher.
BCRX margin peer comparison
Frequently asked questions
What is Biocryst Pharmaceuticals's gross margin?
The current gross margin for BCRX is 97.9% as of Sep 30, 2026.
What is Biocryst Pharmaceuticals's operating margin?
The current operating margin for BCRX is -30.1% as of Sep 30, 2026.
What is Biocryst Pharmaceuticals's EBITDA margin?
As of Sep 30, 2026, BCRX has an EBITDA margin of -28.7%.
What is Biocryst Pharmaceuticals's net margin?
For the period ending Sep 30, 2026, BCRX recorded a net margin of -37.4%.
What are the average margins of BCRX?
Biocryst Pharmaceuticals's average margins over the last 3 years were 97.8% gross, -10.1% operating, -8.9% EBITDA, and -27.8% net.
What are the highest historical margins of BCRX?
Over this 5-year history, BCRX peaked at 99.3% gross in Jun 2022, 39% operating in Dec 2025, 39.7% EBITDA in Dec 2025, and 30.2% net in Dec 2025.
What are the lowest historical margins of BCRX?
Looking back across 5 years, BCRX reached its lowest margins at 95.4% gross in Dec 2021, -113.1% operating in Dec 2021, -77.5% EBITDA in Dec 2021, and -117.1% net in Dec 2021.